SCAI Statement on 'A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study'
LAS VEGAS, May 6 /PRNewswire/ -- Results of the Clopidogrel
Medco Outcomes Study presented today during SCAI's Annual Scientific Sessions found the anti-clotting benefits of clopidogrel
(Plavix) may be reduced when taken concurrently with commonly used heartburn medications called proton pump inhi...
ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome
In order to better prevent blood clots, clopidogrel
can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA). The Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether the combination of clopidogrel
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
- First time IV formulation of clopidogrel, the active ingredient in
PLAVIX(R), is studied in humans -
KING OF PRUSSIA, Pa., Feb. 9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel
AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent...
Matrix registry probes adherence to clopidogrel at 1 year
CHICAGO, Ill. (March 31, 2008) A large community-based registry of patients treated with drug-eluting stents is providing important insight into how long patients with complex coronary artery disease typically stick to their doctors orders to take clopidogrel, a drug that prevents unwanted blood ...
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
Investigational compound reduces risk of major cardiovascular events by 19
percent, significantly improves net clinical benefit despite increased bleeding
TOKYO and INDIANAPOLIS, Nov. 4 /PRNewswire-FirstCall/ -- In the pivotal
Phase III head-to-head TRITON TIMI...
Half of patients undergoing cerebrovascular stent placement respond poorly to clopidogrel
(CHICAGO) A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel. Clopidogrel
(Plavix) and aspirin are medicatio...
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
Duke Clinical Research Institute to lead multinational study with
investigational compound; will include 10,000 medically managed patients with acute coronary syndrome
TOKYO and INDIANAPOLIS, Nov. 4 /PRNewswire-FirstCall/ -- A large Phase
III clinical trial is anticip...
The Benefits of abciximab with clopidogrel for percutaneous coronary intervention Questioned
Primary findings from the Intracoronary Stenting and Antithrombotic Regimen-Rapid// Early Action for Coronary Treatment Trial (ISAR-REACT) has indicated that abciximab use in patients undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg clopidogrel
for less than 2 hour...
Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R))
...ockade and has been in used globally to assess a patient's response to both clopidogrel
and prasugrel in clinical trials as well as in clinical practice within the...leared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel
(Plavix)), and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)...
Clopidogrel in Medical Technology
Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
- Direct-Acting PRT060128 Provides Reversible, High-level Platelet Inhibition with Immediate Onset of Action -
NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 12 /PRNewswire/ --
Portola Pharmaceuticals, a biopharmaceutical company developing innovative
drugs that provide sign...
Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
New analysis of landmark study showed patients taking prasugrel had lower risk of combined endpoint of recurrent heart attack, stroke or cardiovascular death after first event than those taking clopidogrel
TOKYO and INDIANAPOLIS, Aug. 21 /PRNewswire-FirstCall/ -- A new,
Tailored Clopidogrel Dosing Improves PCI Outcomes
Blood test monitors each patient's response to anti-clotting drug
CHICAGO, March 29 /PRNewswire/ -- Using a simple blood test to
individualize the loading dose of a medication that prevents blood clotting
significantly reduces the risk of major cardiovascular complications after
Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
MUNICH, Germany, Sept. 3 /PRNewswire-FirstCall/ -- A sub-analysis of
the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel
compared with clopidogrel
significantly reduced the risk of new or
recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless
of whether ...
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
Sub-group analysis of landmark trial showed prasugrel substantially reduced
risk of heart attack and stent thrombosis compared with clopidogrel
among ACS patients with diabetes
MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were
diabetic and diagnosed with...
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Reductions seen as soon as three days and out to 450 days in patients who received either bare metal or drug-eluting stents
CHICAGO, March 29 /PRNewswire-FirstCall/ -- The investigational
antiplatelet drug prasugrel plus aspirin produced a marked and highly
statistically significant r...
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
...he trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel
(Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on...
Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
... not taking the drugs.
Diabetes Patients on clopidogrel
and Proton Pump Inhibitors at Greater Risk for Cardiovascular Events
New research from the clopidogrel
Medco Outcomes Study (CMOS) has revealed an increa...vascular events in patients with diabetes who take clopidogrel
(the active ingredient in Plavix(R)) and proton pu...
New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
... proton pump inhibitors (PPIs) in conjunction with clopidogrel
increases the risk of hospitalization for a CV eve...being insufficient to yield reliable results.
is one of the world's most prescribed drugs, and r...al sales in 2008. PPIs are often taken along with clopidogrel
to reduce the risk of gastrointestinal bleeding, a...
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
...s not powered to make efficacy comparisons between clopidogrel
and prasugrel based on genetic variations.
Th...ber 2007 (Vol. 357 No.20), compared prasugrel with clopidogrel
in patients with ACS undergoing PCI. In the primar...risk of major bleeding by 32 percent compared with clopidogrel
(2.4 percent vs. 1.8 percent), which included life...
Clopidogrel in Medical Products
VerifyNow Clopidogrel Assay
Description: The VerifyNow Clopidogrel
Assay measures changes in platelet function in response to patients taking Clopidogrel
(Plavix). It uses a specific activator for the P2Y12 pathway, which clopidogrel
inhibits. The assay has not been cleared by the FDA, however, the assay is available for Research Use Only...
Clopidogrel in Medical Dictionary
...ations are allowed to have different ... : The FDA has approved first-time generic formulations for cyclobenzaprine HCl 5-mg tablets (Flexeril), clopidogrel
bisulfate 75-mg tablets (Plavix), and ... Todayâ€™s health care cost crisis is widely feared. In a shocking exposure, Life Extension uncovers a co...
Clopidogrel in Biological News
High-dose anticlotting drug cuts heart attack, death risk in half
...hers found that giving patients at least 600 mg of clopidogrel
before stenting, rather than the standard 300-mg d...er PCI, while minimizing bleeding and costs."
interferes with the action of platelet cells, whic...oronary artery.
To evaluate the effect of the clopidogrel
loading dose, researchers from University of Turin...
UCSD researchers create roadmap to integrin activation
... bleeding complications in chronic use.
In sharp contrast, drugs such as clopidogrel
(Plavix) and aspirin are two examples of antithrombotics that work well in ...tration and are widely used for this purpose.
"Drugs such as aspirin and clopidogrel
work in large part by blocking the activation of GPIIb-IIIa. These drugs d...
Clopidogrel in Biological Technology
Sanofi-aventis Announces Second Quarter 2009 Results
...a slight decline (of 3.2%) due to competition from clopidogrel
besylate in the monotherapy segment in Germany, wh...val of applications for marketing authorization of clopidogrel
filed through the centralized procedure in the Eur...Some of these applications are for formulations of clopidogrel
with a different salt (e.g. besylate) from that us...
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
...taking prasugrel, as compared with patients taking clopidogrel
(Plavix(R)/Iscover(R)), experienced reduced risk o...with prasugrel compared with patients treated with clopidogrel
was 2.8 percent vs. 3.7 percent, respectively (p=0...rel compared with 6.4 percent in patients who took clopidogrel
(p=0.0002). Non-procedure-related heart attacks in...
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
... non-coronary artery bypass graft (non-CABG) major bleeding, including fatal bleeding, was higher with prasugrel (2.2 percent incidence) compared with clopidogrel
(1.7 percent incidence). Compared with the overall study population, a higher risk of serious bleeding among prasugrel patients was most evident in th...
Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
...tion of Senior Vice President, Clinical Development. Dr. Shannon headed Global Clinical Development during Sterling's alliance with Sanofi to develop clopidogrel
(Plavix(R)). Following this, Dr. Shannon joined Sandoz in Switzerland as Head of Drug Registration and Regulatory Affairs. He spearheaded the integra...
Interim Analysis of Data from e-HEALING Registry of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
...registry with 5,000 enrolled patients treated with the
Genous Bio-engineered R stent. The study protocol recommends that patients
receive one month of clopidogrel
treatment after the procedure. Clinical
follow-up takes place at 30 days, six months and 12 months. The primary
endpoint of the registry is target ves...
deCODE genetics Announces Second Quarter 2008 Financial Results
...telet aggregation without increasing bleeding time
as monotherapy, and further demonstrate that in combination with
clopidogrel alone, as well as with clopidogrel
and aspirin, DG041 provides
additional antiplatelet effect without prolonging bleeding time.
-- Diagnostics: Glaucoma. In the second quarter, the co...
Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
... estimated to be 6% favorably impacted by the residual sales of generic clopidogrel
bisulfate in the first quarter of 2007, after which time the generic ...0 million to $250 million. Estimated total U.S. prescription demand for clopidogrel
bisulfate (branded and generic) increased by 4% in the first quarter of...
New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
...olled trial designed to investigate in 14000 patients, whether the use
of a clopidogrel
600mg loading dose, followed by an intensified clopidogrel
dosing regimen (...s at 150mg follow by 75mg) yields improved clinical
outcomes as compared to clopidogrel
300mg loading dose followed by 75mg in
ACS patients managed with an early i...
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
...the safety and efficacy of
prasugrel compared with clopidogrel
(Plavix(R)/Iscover(R)) in reducing
ischemic events...- 19 percent relative risk reduction compared with clopidogrel
in all ACS patients in the primary composite e...ar death (p -- 52 percent reduction compared with clopidogrel
in stent thrombosis (p -- 30 percent relative...
PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
...se clots are a rare but serious complication of drug-eluting
stents and must be prevented with a strict regimen of aspirin plus the
clot-reducing drug clopidogrel
for at least one year after the artery is
opened with a stent. "By emitting tiny amounts of medication, drug-eluting
stents reduce the regrowth of sca...